Ignite Creation Date:
2024-05-06 @ 1:32 AM
Last Modification Date:
2024-10-26 @ 11:05 AM
Study NCT ID:
NCT01831726
Status:
COMPLETED
Last Update Posted:
2017-03-20
First Post:
2013-04-11
Brief Title:
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Tumor Pathway Activations Inhibited by Dovitinib |
Keywords:
| Name | View |
|---|---|
| amplification | View |
| Solid tumor malignancy | View |
| hematologic malignancy | View |
| mutation | View |
| translocations | View |
| FGFR | View |
| PDGFR | View |
| VEGF | View |
| cKIT | View |
| FLT3 | View |
| CSR1 | View |
| Trk | View |
| RET | View |
| TKI258 | View |
| dovitinib | View |
| signature | View |
| AML | View |
| acute myelogenous leukemia | View |
| GIST | View |
| gastrointestinal stromal tumor | View |
| Head and Neck cancer | View |
| Melanoma | View |
| NSCLC | View |
| non-small cell lung carcinoma | View |
| lung cancer | View |
| ovarian cancer | View |
| thyroid cancer | View |